Forum Topic News
  • Conversation: Bicycle Therapeutics and Cancer Research UK Announce Initiation of First Clinical Study of a Bicyclic Peptide (Bicycle®)

    • February 14, 2018 11:36 AM GMT
      • Post(s)
        548

      Bicycle Therapeutics and Cancer Research UK Announce Initiation of First Clinical Study of a Bicyclic Peptide (Bicycle®)

      LONDON & CAMBRIDGE, United Kingdom & BOSTON--(BUSINESS WIRE)--Cancer Research UK and Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, announced today that the first patient has been dosed in their Phase I/IIa trial evaluating BT1718 in patients with advanced solid tumors. BT1718 is a first-in-class Bicycle Toxin Conjugate being developed by Bicycle Therapeutics that targets Membrane Type 1 Matrix Metalloproteinase (MT1-MMP/MMP-14), which has been shown to be highly expressed in solid tumors.
      “The initiation of this study is a landmark event for the company and for our technology,” said Maria Koehler, M.D., Ph.D., Chief Medical Officer of Bicycle Therapeutics. “BT1718 is the first clinical candidate from our pipeline of Bicycles, a brand-new class of chemically synthesized medicines. We believe that Bicycles, because of their small size and exquisite selectivity, could provide meaningful efficacy to patients suffering from cancer and avoid the toxicities associated with other classes of highly potent anti-cancer drugs. We are delighted to be exploring its potential in collaboration with Cancer Research UK.”
      Read more: http://bit.ly/2EnDtWN

Add Reputation

Do you want to add reputation for this member by this post?

or cancel